Multiple Sclerosis (MS) Drug Market

Forbes  Mar 24  Comment 
In the old days, blockbuster drugs were moderately expensive pills taken by hundreds of thousands of patients. Think blood pressure, cholesterol and diabetes pills. But today, many blockbusters are designed to target much less common diseases,...
Reuters  Mar 23  Comment 
Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.
Motley Fool  Mar 8  Comment 
Despite plenty of research dollars being spent, little is still known about the root causes of multiple sclerosis. That's why this latest study is so encouraging for a select group of MS patients, as it may one day lead to a cure.
Benzinga  Feb 27  Comment 
Receptos Inc (NASDAQ: RCPT) gained more than 2 percent after its chief executive said recent data on a promising colitis drug candidate are "as good as it gets." After popping about 2 percent, shares of the drug development company changed...
FierceBiotech  Feb 23  Comment 
After seeing its reputation as a leader in multiple sclerosis erode over recent years, Merck KGaA has decided to carve back the number of staffers working in preclinical R&D in the field.
GenEng News  Feb 18  Comment 
Researchers at the Toronto-based Center for Addiction and Mental Health (CAMH) say they have discovered a promising new approach to treat multiple sclerosis (MS). In a new study, they've identified a previously unknown change in the spinal cord...
GenEng News  Feb 17  Comment 
Researchers at Trinity College Dublin have discovered what they term a “marvel” molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new noninvasive treatments for...
MedPage Today  Feb 11  Comment 
(MedPage Today) -- Multiple sclerosis patients had fewer new lesions with stem-cell transplant versus mitoxantrone.
The Hindu Business Line  Feb 11  Comment 
Natco Pharma Ltd has filed Abbreviated New Drug Applications (ANDAs) for fingolimod capsules and cabazitaxel injection with the US Federal Drug Administration (USFDA). The filing was done...
FierceBiotech  Feb 1  Comment 
You can add another clinical stage program for remyelination to your watch list. Acorda's early-stage drug for targeting the root cause of multiple sclerosis has cleared its first hurdle in the clinic, passing its Phase I safety challenge with a...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki